EA200400352A1 - Органолептически приемлемые распадающиеся во рту композиции - Google Patents

Органолептически приемлемые распадающиеся во рту композиции

Info

Publication number
EA200400352A1
EA200400352A1 EA200400352A EA200400352A EA200400352A1 EA 200400352 A1 EA200400352 A1 EA 200400352A1 EA 200400352 A EA200400352 A EA 200400352A EA 200400352 A EA200400352 A EA 200400352A EA 200400352 A1 EA200400352 A1 EA 200400352A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mouth
organoleptically acceptable
acceptable dimensional
compositions dissolving
dimensional compositions
Prior art date
Application number
EA200400352A
Other languages
English (en)
Russian (ru)
Inventor
Транг Т. Ли
Блейк К. Людвиг
Джозеф П. Рео
Юдэй Дж. Шах
Кен Ямамото
Original Assignee
Фармация Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация Корпорейшн filed Critical Фармация Корпорейшн
Publication of EA200400352A1 publication Critical patent/EA200400352A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA200400352A 2001-09-26 2002-09-23 Органолептически приемлемые распадающиеся во рту композиции EA200400352A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32535601P 2001-09-26 2001-09-26
PCT/US2002/030048 WO2003026697A2 (en) 2001-09-26 2002-09-23 Organoleptically acceptable intraorally disintegrating compositions

Publications (1)

Publication Number Publication Date
EA200400352A1 true EA200400352A1 (ru) 2004-12-30

Family

ID=23267542

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200400352A EA200400352A1 (ru) 2001-09-26 2002-09-23 Органолептически приемлемые распадающиеся во рту композиции
EA200400357A EA200400357A1 (ru) 2001-09-26 2002-09-23 Дезинтегрирующиеся в ротовой полости композиции валдекоксиба

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200400357A EA200400357A1 (ru) 2001-09-26 2002-09-23 Дезинтегрирующиеся в ротовой полости композиции валдекоксиба

Country Status (25)

Country Link
US (1) US20030181501A1 (enExample)
EP (2) EP1429736A2 (enExample)
JP (2) JP2005512964A (enExample)
KR (2) KR20040058189A (enExample)
CN (2) CN1633281A (enExample)
AP (2) AP2004002998A0 (enExample)
AR (1) AR037239A1 (enExample)
BR (2) BR0212861A (enExample)
CA (2) CA2461630A1 (enExample)
CO (2) CO5570659A2 (enExample)
EA (2) EA200400352A1 (enExample)
EC (1) ECSP045029A (enExample)
GE (1) GEP20063856B (enExample)
HK (1) HK1079988A1 (enExample)
IL (2) IL160855A0 (enExample)
IS (2) IS7178A (enExample)
MA (2) MA27542A1 (enExample)
MX (2) MXPA04002798A (enExample)
NO (2) NO20041258L (enExample)
OA (2) OA13060A (enExample)
PL (2) PL369297A1 (enExample)
TN (2) TNSN04045A1 (enExample)
WO (2) WO2003026623A1 (enExample)
YU (1) YU34804A (enExample)
ZA (2) ZA200401953B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002557A1 (en) * 2003-07-03 2005-01-13 Warner-Lambert Company Llc Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof
US20050186271A1 (en) * 2004-02-24 2005-08-25 Sheskey Paul J. Process for dispersing a fluid in a mass of solid particles
JP5551852B2 (ja) * 2004-08-10 2014-07-16 味の素株式会社 苦味の低減したナテグリニド含有製剤
CN101115469A (zh) * 2004-12-28 2008-01-30 卫材R&D管理有限公司 速崩片及其制造方法
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JPWO2007072840A1 (ja) * 2005-12-20 2009-05-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 脂溶性薬物を含有する口腔内速崩錠
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
WO2007087188A2 (en) * 2006-01-20 2007-08-02 Merck & Co., Inc. Taste-masked tablets and granules
US20070196494A1 (en) * 2006-02-17 2007-08-23 Arnaud Grenier Low-friability, patient-friendly orally disintegrating formulations
CA2687124A1 (en) * 2006-05-19 2007-12-13 Somaxon Pharmaceuticals, Inc. Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia
EP2164462B1 (de) * 2007-06-06 2017-05-31 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
US8685457B2 (en) * 2007-06-06 2014-04-01 Basf Se Pharmaceutical formulation for the production of rapidly disintegrating tablets
EP2164460B1 (de) * 2007-06-06 2017-08-09 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
US20100184785A1 (en) * 2007-06-06 2010-07-22 Basf Se Pharmaceutical formulation for the production of chewable tablets and lozenges
WO2009021106A1 (en) * 2007-08-07 2009-02-12 Acelrx Pharmaceuticals, Inc. Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms
WO2009118589A2 (en) 2008-03-24 2009-10-01 Wockhardt Research Centre Orally disintegrating compositions of rhein or diacerein
US8945592B2 (en) * 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
KR101704156B1 (ko) * 2008-11-25 2017-02-07 미쓰비시 타나베 파마 코퍼레이션 구강 내 속붕괴성정을 제조하기 위한 혼합물
EP2440210A4 (en) 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
FR2968995B1 (fr) * 2010-12-16 2013-03-22 Sanofi Aventis Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage
CN106822007B (zh) 2015-09-11 2021-12-31 西姆莱斯股份公司 口服制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
SK74396A3 (en) * 1995-06-13 1997-04-09 American Home Prod Organoleptically acceptable oral pharmaceutical compositions
DE69621143T2 (de) * 1995-10-20 2002-11-07 Pharmacia & Upjohn Co., Kalamazoo Blisterpackung
AU3004997A (en) * 1996-05-17 1997-12-09 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
EP0863134A1 (en) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
US6465009B1 (en) * 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
HRP20010582A2 (en) * 1999-12-08 2002-08-31 Pharmacia Corp Valdecoxib compositions
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6800297B2 (en) * 2000-06-15 2004-10-05 Acusphere, Inc. Porous COX-2 inhibitor matrices and methods of manufacture thereof
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
CA2419592A1 (en) * 2000-08-18 2002-02-28 Pharmacia Corporation Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor

Also Published As

Publication number Publication date
EA200400357A1 (ru) 2004-08-26
CO5570659A2 (es) 2005-10-31
EP1429736A2 (en) 2004-06-23
BR0212778A (pt) 2004-12-07
WO2003026623A8 (en) 2004-09-30
OA13060A (en) 2006-11-10
MXPA04002652A (es) 2004-06-07
IS7178A (is) 2004-03-11
CN1633281A (zh) 2005-06-29
WO2003026623A1 (en) 2003-04-03
PL369297A1 (en) 2005-04-18
MA27682A1 (fr) 2006-01-02
US20030181501A1 (en) 2003-09-25
KR20040058189A (ko) 2004-07-03
PL369298A1 (en) 2005-04-18
AP2004002998A0 (en) 2004-03-31
TNSN04045A1 (fr) 2006-06-01
TNSN04047A1 (fr) 2006-06-01
WO2003026697A3 (en) 2003-07-03
JP2005506987A (ja) 2005-03-10
ZA200402364B (en) 2005-01-13
IS7177A (is) 2004-03-11
NO20041258L (no) 2003-03-27
HK1079988A1 (zh) 2006-04-21
WO2003026697A2 (en) 2003-04-03
IL160848A0 (en) 2004-08-31
JP2005512964A (ja) 2005-05-12
CN1703203A (zh) 2005-11-30
MXPA04002798A (es) 2004-07-05
ZA200401953B (en) 2005-05-09
NO20041532L (no) 2004-04-15
OA12707A (en) 2006-06-26
AP2004002999A0 (en) 2004-03-31
ECSP045029A (es) 2004-04-28
BR0212861A (pt) 2004-10-05
MA27542A1 (fr) 2005-10-03
CA2461630A1 (en) 2003-04-03
CO5570684A2 (es) 2005-10-31
IL160855A0 (en) 2004-08-31
CA2461044A1 (en) 2003-04-03
YU34804A (sh) 2006-08-17
KR20040044990A (ko) 2004-05-31
GEP20063856B (en) 2006-06-26
AR037239A1 (es) 2004-11-03
EP1490035A1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
EA200400357A1 (ru) Дезинтегрирующиеся в ротовой полости композиции валдекоксиба
EA200301223A1 (ru) Лекарственные формы окскарбазепина
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
ATE402176T1 (de) Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
ATE414519T1 (de) Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit
AP2002002637A0 (en) Novel piperazine
FR17C1043I2 (fr) Nouvelles compositions immunogenes pour la prevention et le traitement de la meningite a meningocoques
ATE361288T1 (de) N-(3,-dimethylindolin-6-yl)ä2-ä(4-
JO2371B1 (en) 4-phenyl-pyridine derivatives
AR020015A1 (es) Composiciones de celecoxib
TR200400072T4 (tr) Novel Biarylcarboxamides Biarylcarboxamide Nouveaux Biarylcarboxamides
HUP0000487A2 (hu) Neurokinin antagonistaként alkalmazható szubsztituált oximszármazékok
NO20043341L (no) Fremgangsmate for fremstilling av scopinestere
ATE410426T1 (de) Heterocyclische verbindungen alsccr5-antagonisten
MXPA04006555A (es) Piridazinodionas-3,4-disustituidas como antagonistas de receptor de quimiocina cxc.
DK1392348T3 (da) Behandling af demens og neurodegenerative sygdomme med moderate doser af LHRH antagonister
ECSP055844A (es) Nuevos compuestos triciclicos
EA200300392A1 (ru) Производные пиперазина с мостиковой связью
EP1543166A4 (en) SYNERGETIC COMPOSITIONS FOR PREVENTING AND TREATING THE ACQUIRED IMMUNE WEAKNESS SYNDROME
IL162983A (en) Use of imatinib for the manufacture of pharmaceutical compositions for the treatment of rheumatoid arthritis
GEP20074051B (en) Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders
EA200400296A1 (ru) Применение ингибиторов il-18 при расстройствах в виде гиперчувствительности
TR200102009T2 (tr) Serebral işlemi profilaksı ve tedavisi için formül I'e göre bileşiklerin kullanımı
NO20063012L (no) Fremgangsmaten for syntesen av perindopril og farmasoytisk akseptable salter derav
MXPA04004980A (es) Antagonistas del receptor ccr-3.